1. Arya SS, Rookes JE, Cahill DM, Lenka SK. Vanillin: a review on the therapeutic prospects of a popular flavouring molecule. Adv Tradit Med (ADTM) 2021; 21: 1-17.
2.
Azam S, Jakaria M, Kim IS, Kim J, Haque ME, Choi DK. Regulation of Toll-like receptor (TLR) signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: Focus on TLR4 signaling. Front Immunol 2019; 10: 1000.
3.
Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564-573.
4.
Ciranna L. Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol 2006; 4: 101-114.
5.
Chen Y, Qin C, Huang J, Tang X, Liu C, Huang K, Xu J, Guo G, Tong A, Zhou L. The role of astrocytes in oxidative stress of central nervous system: A mixed blessing. Cell Prolif 2020; 53: e12781.
6.
DeMaagd G, Philip A. Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P T 2015; 40: 504-532.
7.
Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017; 9: a028035.
8.
Fang C, Lv L, Mao S, Dong H, Liu B. Cognition deficits in Parkinson’s disease: Mechanisms and treatment. Parkinsons Dis 2020; 2020: 2076942.
9.
Hussain R, Zubair H, Pursell S, Shahab M. Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches. Brain Sci 2018; 8: 177.
10.
Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, Zaheer S, Iyer SS, Zaheer A. Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 2016; 1: 1003.
11.
Kim ME, Na JY, Park YD, Lee JS. Anti-neuroinflammatory effects of vanillin through the regulation of inflammatory factors and NF-kB signaling in LPS-stimulated microglia. Appl Biochem Biotechnol 2019; 187: 884-893.
12.
Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009; 14: 478-500.
13.
Li Y, Xia Y, Yin S, Wan F, Hu J, Kou L, Sun Y, Wu J, Zhou Q, Huang J, Xiong N, Wang T. Targeting microglial a-synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in Parkinson’s disease. Front Immunol 2021; 12: 719807.
14.
Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson’s disease: an update. J Parkinsons Dis 2011; 1: 19-33.
15.
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 2014; 20: 1126-1167.
16.
Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG; Arizona Parkinson’s Disease Consortium. Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol 2012; 71: 520-530.
17.
Pritchett D, Taylor AM, Barkus C, Engle SJ, Brandon NJ, Sharp T, Foster RG, Harrison PJ, Peirson SN, Bannerman DM. Searching for cognitive enhancement in the Morris water maze: better and worse performance in D-amino acid oxidase knockout (Dao(-/-)) mice. Eur J Neurosci 2016; 43: 979-989.
18.
Sirangelo I, Sapio L, Ragone A, Naviglio S, Iannuzzi C, Barone D, Giordano A, Borriello M. Vanillin prevents doxorubicin-induced apoptosis and oxidative stress in Rat H9c2 cardiomyocytes. Nutrients 2020; 12: 2317.
19.
Sun F, Liu F. Platycodin D inhibits MPP+-induced inflammatory response in BV-2 cells through the TLR4/MyD88/NF-κB signaling pathway. J Recept Signal Transduct Res 2020; 40: 479-485.
20.
Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J 2018; 285: 3657-3668.
21.
Yan X, Liu DF, Zhang XY, Liu D, Xu SY, Chen GX, Huang BX, Ren WZ, Wang W, Fu SP, Liu JX. Vanillin protects dopaminergic neurons against inflammation-mediated cell death by inhibiting ERK1/2, P38 and the NF-κB signaling pathway. Int J Mol Sci 2017; 18: 389.
